In the Spotlight...

Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance

Scolaro et al. showed that cytidine deaminase (CDA) was upregulated in several immunotherapy-resistant tumors and contributed to the uridine diphosphate (UDP) pool in the extracellular milieu. Activat...

Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies

Hammer et al. showed that deletion of genes for the CD54 (ICAM-1, binds LFA-1) and CD58 (LFA-3, binds CD2) adhesion molecules in B2M-/- (HLA-Ilo) target cells reduced their sensitivity to NK cell “m...

GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy

By overexpressing the glucose transporter GLUT1 in two clinically relevant CAR T cells (19-28z and IL13Rα2-BBz), Shi and Kotchetkov et al. asked if improved glucose uptake by the CAR T cells in a gluc...

Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers

DC microvesicle NPs (MVNPs) were produced by mixing cationic NPs with tumor cell lysate, incubating them with DCs, and releasing NP microvesicles via UV irradiation. MVNPs expressed DC markers and pro...

Previous Digests

A closer look at inflammation suggests new treatment approach for PDAC

July 10, 2024

Pancreatic ductal adenocarcinoma (PDAC) remains refractory to immunotherapy due to a compromised tumor immune microenvironment (TIME) with dysfunctional T cells, suppressive myeloid and regulatory T cells (Tregs), and a sparsity of neoantigens and antigen-presenting cells. Patients with a history...

JAK-ing up ICB responses with JAK inhibitors

July 3, 2024

One of the main outstanding issues for cancer immunotherapy is how to improve the efficacy of immune checkpoint blockade (ICB) in subsets of patients who currently do not benefit. Two recent back-to-back publications in Science tackled this issue by...

Three’s company: immune triads license CD8+ T cell-mediated antitumor immunity

June 26, 2024

CD4+ T cells are known to “help” CD8+ T cells by licensing their cytotoxic functions in tumors, but exactly how this help is given is not entirely understood. To better understand how CD4+ T cells contribute to CD8+ T...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.